Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
Provided By GlobeNewswire
Last update: Nov 7, 2024
Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study
Highlights Company’s Leadership and Progress in Developing Iopofosine I 131 as Treatment for Waldenstrom’s Macroglobulinemia
Read more at globenewswire.com
